CSC
NVAX icon

Caldwell Sutter Capital’s Novavax NVAX Stock Holding History

Caldwell Sutter Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$471 Hold
50
– – ﹤0.01% 892
2026
Q1 		$407 Hold
50
– – ﹤0.01% 857
2025
Q4 		$336 Hold
50
– – ﹤0.01% 844
2025
Q3 		$434 Buy
50
+25
+100% +$195 ﹤0.01% 835
2025
Q2 		$158 Hold
25
– – ﹤0.01% 831
2025
Q1 		$160 Hold
25
– – ﹤0.01% 859
2024
Q4 		$201 Hold
25
– – ﹤0.01% 867
2024
Q3 		$316 Hold
25
– – ﹤0.01% 869
2024
Q2 		$317 Hold
25
– – ﹤0.01% 879
2024
Q1 		$120 Hold
25
– – ﹤0.01% 892
2023
Q4 		$120 Hold
25
– – ﹤0.01% 927
2023
Q3 		$181 Hold
25
– – ﹤0.01% 855
2023
Q2 		$186 Buy
+25
New +$197 ﹤0.01% 842
2023
Q1 		– Sell
-1,400
Closed -$14.4K – 567
2022
Q4 		$14.4K Buy
+1,400
New +$24.7K 0.01% 240

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Caldwell Sutter Capital's NVAX Position: Q2 2026 in Review

Caldwell Sutter Capital held its Novavax (NVAX) position steady in Q2 2026 at 50 shares worth $471. The position accounts for ﹤0.01% of the portfolio, ranked #892.

Caldwell Sutter Capital first reported a position in NVAX in Q4 2022 and has held it in 14 quarters since. The position peaked at $14.4K in Q4 2022. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Caldwell Sutter Capital held 50 shares of Novavax worth $471 as of Q2 2026.
  • Caldwell Sutter Capital left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Caldwell Sutter Capital's portfolio in Q2 2026, its #892 holding.
  • Caldwell Sutter Capital first reported a position in Novavax in Q4 2022 and has held it in 14 quarters since.
  • Caldwell Sutter Capital's Novavax position peaked at $14.4K in Q4 2022.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Caldwell Sutter Capital's 13F filing for Q2 2026, filed 5 Aug 2026.